Biosensia Raises €1.2M in Funding

Biosensia, a Dublin, Ireland-based point of care diagnostics company, recently raised €1.2m in funding.

The round was led by ACT Venture Capital, through its AIB Start-up Accelerator Fund, with participation from existing investors Seroba BioVentures and Atlantic Bridge.

The company intends to use the funding to secure CE mark and FDA regulatory approval for its products in Europe and the US and advance its commercial partnership strategy.

Led by CEO Diarmuid Flavin, Biosensia has developed RapiPlex, a novel, multiplexing point of care in vitro diagnostics platform that gives access to a broad range of diagnostic applications including acute phase diagnostics, prognostic diagnostic panels and companion diagnostics at the point of care.



Join the discussion